This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Study Preview



Study Title and Description

Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome.



Key Questions Addressed
1 RCTs and other Comparative studies
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome.
Author Kuhnt K., Fuhrmann C., Köhler M., Kiehntopf M., Jahreis G.
Country Department of Nutritional Physiology, Institute of Nutrition, and.
Year 2014
Numbers Pubmed ID: 24553695

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Comparative Studies
Arms
Number Title Description Comments
1 SDA+ALA echium oil
  • Comments Comments (
    0
    ) |
2 "Fish oil" (DHA+EPA) fish oil mixed with olive oil (to be isocaloric with echium oil arm)
  • Comments Comments (
    0
    ) |

Design Details
Question... Follow Up Answer Follow-up Answer
Study Design Trial: Randomized Parallel (Omega-3 vs. Control; Omega-3 + X vs. X)
  • Comments Comments (
    0
    ) |
Country in which study conducted (where subjects live) Germany
  • Comments Comments (
    0
    ) |
Funding source No industry relationship reported (funding or affiliations reported)
  • Comments Comments (
    0
    ) |
Eligibility Criteria: Normolipidemic and normal-weight (BMI 18-25) individuals were recruited for 2 age groups: group I, 20-35 y; and group II 49-69 y. Older overweight individuals were recruited for echium oil (EO) intervention only (49-69 y; BMI >25 with markers of metabolic syndrome or BMI >= 30).
  • Comments Comments (
    0
    ) |
Comment about Eligibility Criteria: Patients with markers of metabolic syndrome were mainly enlisted from the diabetes research center. This subgroup - EO III (older overweight individuals who were recruited for echium oil intervention only; 49-69 y; BMI >25 with markers of metabolic syndrome) was not included in this systematic review.
  • Comments Comments (
    0
    ) |
Study Population Primary Prevention, Healthy
  • Comments Comments (
    0
    ) |
Duration of Intervention 8 weeks
  • Comments Comments (
    0
    ) |
Conflict of interest No conflict of interest (explicitly stated)
  • Comments Comments (
    0
    ) |
Does the study report a subgroup analysis for an outcome of interest? ... Which subgroups? Yes ... age groups (by study design)
  • Comments Comments (
    0
    ) |
Does the study report a regression analysis with interaction terms for an outcome of interest? No
  • Comments Comments (
    0
    ) |
Does the study report an analysis of the association between n-3 biomarkers and an outcome of interest? Yes
  • Comments Comments (
    0
    ) |
Study start date(s) March 2011 (from clinicaltrials.gov)
  • Comments Comments (
    0
    ) |


Baseline Characteristics
Question SDA+ALA "Fish oil" (DHA+EPA) Total Comments
AnswerFollow-up AnswerFollow-up AnswerFollow-up
Baseline Diseases/Conditions No data entered.
Baseline characteristics, continuous EOI: 28; EOII: 59; EOIII: 61 FOI: 27; FOII: 60
  • Comments Comments (
    0
    ) |
EOI: 2.9; EOII: 5.7; EOIII: 6.3 FOI: 2.5; FOII: 4.2
  • Comments Comments (
    0
    ) |
EOI: 125; EOII: 135; EOIII: 141 FOI: 4.59; FOII: 5.73
  • Comments Comments (
    0
    ) |
EOI: 10.4; EOII: 19.9; EOIII: 15.6 mmol/L
  • Comments Comments (
    0
    ) |
EOI: 82; EOII: 90; EOIII: 91 FOI: 0.62; FOII: 0.80
  • Comments Comments (
    0
    ) |
EOI: 8.9; EOII: 12; EOIII: 7.9 FOI: 2.49; FOII: 3.08
  • Comments Comments (
    0
    ) |
nd mmol/L
  • Comments Comments (
    0
    ) |
EOI: 4.52; EOII: 5.71; EOIII: 6.30 FOI: 0.66; FOII: 0.70
  • Comments Comments (
    0
    ) |
mmol/L FOI: 1.65; FOII: 1.92
  • Comments Comments (
    0
    ) |
EOI: 0.68; EOII: 1.24; EOIII: 1.02 mmol/L
  • Comments Comments (
    0
    ) |
EOI: 1.48; EOII: 1.58; EOIII: 1.33 FOI: 0.34; FOII: 0.59
  • Comments Comments (
    0
    ) |
mmol/L FOI: 0.77; FOII: 0.90
  • Comments Comments (
    0
    ) |
EOI: 0.67; EOII: 0.66; EOIII: 0.75 mmol/L
  • Comments Comments (
    0
    ) |
EOI: 1.43; EOII: 1.58; EOIII: 1.33 FOI: 0.21; FOII: 0.32
  • Comments Comments (
    0
    ) |
EOI: 0.30; EOII: 0.47; EOIII: 0.32 FOI: 136; FOII: 136
  • Comments Comments (
    0
    ) |
EOI: 0.89; EOII: 1.14; EOIII: 1.82 FOI: 13.6; FOII: 18.7
  • Comments Comments (
    0
    ) |
EOI: 0.36; EOII: 0.42; EOIII: 0.88 FOI: 88; FOII: 88
  • Comments Comments (
    0
    ) |
EOI: 22; EOII: 23.5; EOIII: 30.1 FOI: 7.7; FOII: 7.8
  • Comments Comments (
    0
    ) |
EOI: 2.3; EOII: 2.4; EOIII: 3.3 FOI: 21.5; FOII: 24.8
  • Comments Comments (
    0
    ) |
mmol/L FOI: 2.6; FOII: 3.1
  • Comments Comments (
    0
    ) |
mmol/L
  • Comments Comments (
    0
    ) |
Male, percent EOI: 50; EOII: 55; EOIII: 53 FOI: 50; FOII: 56 53
  • Comments Comments (
    0
    ) |
Race nd nd nd
  • Comments Comments (
    0
    ) |
Comments about baseline data No data entered.
Baseline diet description Higher age and BMI were related to a greater intake of total energy, protein, fat, fibers, and cholesterol. Overall, no significant differences were seen compared with baseline or between the treatments.
  • Comments Comments (
    0
    ) |
Baseline omega-3 intake nd, but the participants were encouraged to avoid consuming fish, fish oils, n-3 PUFA-rich foods and oils (linseed and rapeseed oils) margarine, and common sunflower oil.
  • Comments Comments (
    0
    ) |
Does this study report baseline omega-3 biomarker data? Yes Yes Yes
  • Comments Comments (
    0
    ) |



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Events (n) At Risk (N) Follow-up time Comments
SDA+ALA nd nd
  • Comments Comments (
    0
    ) |
"Fish oil" (DHA+EPA)

Quality Dimensions
Dimension Value Notes Comments
Was the allocation sequence (RANDOMIZATION METHOD) adequately generated? Low risk
  • Comments Comments (
    0
    ) |
Was ALLOCATION adequately concealed (prior to assignment)? Low risk
  • Comments Comments (
    0
    ) |
Were PARTICIPANTS adequately BLINDED? Yes
  • Comments Comments (
    0
    ) |
Were OUTCOME ASSESSORS adequately BLINDED? Yes
  • Comments Comments (
    0
    ) |
Incomplete outcome data (ATTRITION BIAS) due to amount, nature or handling of incomplete outcome data Low risk
  • Comments Comments (
    0
    ) |
Is there evidence of SELECTIVE OUTCOME REPORTING bias (Yes/No)? No
  • Comments Comments (
    0
    ) |
INTENTION-TO-TREAT analysis? (Yes/No) No
  • Comments Comments (
    0
    ) |
Group SIMILARITY AT BASELINE (**GENERAL**) Low risk patients with metabolic syndrome were included in EO subgroup (EOIII). This subgroup is not comparable to any other groups but was not included in this systematic review
  • Comments Comments (
    0
    ) |
Was there incomplete COMPLIANCE with interventions across groups? Unclear monitored but data not reported
  • Comments Comments (
    0
    ) |
Group SIMILARITY AT BASELINE (**OMEGA-3**) Low risk
  • Comments Comments (
    0
    ) |
Additional Bias: Bias due to problems not covered elsewhere in the table.
  • Comments Comments (
    0
    ) |
If outcome assessor blinding risk of bias is different for different outcomes (eg, lipids vs. MI), choose HIGH risk of bias and describe in Notes
  • Comments Comments (
    0
    ) |
If attrition risk of bias is different for different outcomes (eg, lipids vs. MI) or different time points (eg, 1 year vs. 5 years), choose HIGH risk of bias and describe in Notes No
  • Comments Comments (
    0
    ) |

Quality Rating
No quality rating data was found.